GERMANI, MARCO MARIA
 Distribuzione geografica
Continente #
NA - Nord America 334
EU - Europa 280
AS - Asia 100
AF - Africa 33
OC - Oceania 1
Totale 748
Nazione #
US - Stati Uniti d'America 332
IT - Italia 170
SG - Singapore 67
SE - Svezia 48
CI - Costa d'Avorio 21
DE - Germania 17
CN - Cina 16
BG - Bulgaria 15
GB - Regno Unito 9
PL - Polonia 8
SN - Senegal 7
FI - Finlandia 4
HK - Hong Kong 4
KR - Corea 4
NG - Nigeria 4
JP - Giappone 3
VN - Vietnam 3
AT - Austria 2
CA - Canada 2
FR - Francia 2
IN - India 2
AU - Australia 1
CH - Svizzera 1
CZ - Repubblica Ceca 1
EG - Egitto 1
ES - Italia 1
IE - Irlanda 1
KH - Cambogia 1
NL - Olanda 1
Totale 748
Città #
Chandler 51
Boardman 29
Fairfield 29
Florence 29
Singapore 29
Milan 26
New York 26
Abidjan 21
Sofia 15
Pisa 14
Bremen 12
Lawrence 12
Princeton 12
Ashburn 11
Wilmington 10
Medford 9
Houston 8
Los Angeles 8
Warsaw 8
Woodbridge 8
Dakar 7
Ogden 7
Rome 7
Shanghai 7
Ann Arbor 6
Seattle 6
Cambridge 5
Dallas 5
London 5
Kent 4
Lagos 4
Polverigi 4
Seoul 4
Verona 4
Coreglia Antelminelli 3
Fukuroi 3
Genoa 3
Helsinki 3
Misinto 3
Munich 3
Pistoia 3
San Diego 3
San Miniato Basso 3
Seacroft 3
Alghero 2
Anzio 2
Buti 2
Carini 2
Castiglione Chiavarese 2
Chiari 2
Civitanova Marche 2
Cologno Monzese 2
Hong Kong 2
Hyderabad 2
Noventa di Piave 2
Osimo 2
Perugia 2
Salerno 2
Tempe 2
Turin 2
Vienna 2
York 2
Adria 1
Berlingo 1
Brno 1
Cairo 1
Cascina 1
Città della Pieve 1
Clifton 1
Darmstadt 1
Dublin 1
Frankfurt am Main 1
Lappeenranta 1
Livorno 1
Marseille 1
Melbourne 1
Montereale Valcellina 1
Peccioli 1
Phnom Penh 1
Pontedera 1
San Francisco 1
Sant Joan Despí 1
Stockholm 1
Toronto 1
Torrevecchia Pia 1
Vicopisano 1
Washington 1
Totale 533
Nome #
Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis 85
Immune checkpoint inhibitors in pmmr metastatic colorectal cancer: A tough challenge 60
Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study 50
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies 49
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO 48
Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications 47
Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer 42
The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features 42
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development 42
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies 41
Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials 38
EGFR Amplification in Metastatic Colorectal Cancer 32
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature 32
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients 29
Total neoadjuvant treatment and organ preservation strategies in the management of localized rectal cancer: A narrative review and evidence-based algorithm 26
Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors 24
Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability 21
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer 19
Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study 19
The Evolving Landscape of Immunotherapy in Locally Advanced Rectal Cancer Patients 15
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial 11
Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analisys of Tribe and Tribe-2 Studies by GONO 8
A Misleading Case of NTRK-Rearranged Papillary Thyroid Carcinoma 6
Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors 5
Treatment of patients with BRAFV600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset 4
Predicting early recurrence after resection of initially unresectable colorectal liver metastases: the role of baseline and pre-surgery clinical, radiological and molecular factors in a real-life multicentre experience 4
Predictive Impact of RNF43 Mutations in Patients With Proficient Mismatch Repair/Microsatellite Stable BRAFV600E-Mutated Metastatic Colorectal Cancer Treated With Target Therapy or Chemotherapy 4
Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV 3
Totale 806
Categoria #
all - tutte 4.779
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.779


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203 0 0 0 0 0 0 0 0 0 0 0 3
2020/202167 0 2 3 0 4 38 0 0 4 1 0 15
2021/2022104 4 0 4 0 13 15 1 4 9 11 13 30
2022/2023240 22 36 17 14 17 26 6 13 52 0 31 6
2023/2024316 18 23 40 21 34 31 32 8 21 17 39 32
2024/202576 15 36 21 4 0 0 0 0 0 0 0 0
Totale 806